These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25924924)

  • 1. Systematic discovery of drug interaction mechanisms.
    Chevereau G; Bollenbach T
    Mol Syst Biol; 2015 Apr; 11(4):807. PubMed ID: 25924924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial interactions: mechanisms and implications for drug discovery and resistance evolution.
    Bollenbach T
    Curr Opin Microbiol; 2015 Oct; 27():1-9. PubMed ID: 26042389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantifying the Determinants of Evolutionary Dynamics Leading to Drug Resistance.
    Chevereau G; Dravecká M; Batur T; Guvenek A; Ayhan DH; Toprak E; Bollenbach T
    PLoS Biol; 2015; 13(11):e1002299. PubMed ID: 26581035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic interactions that select against resistance.
    Chait R; Craney A; Kishony R
    Nature; 2007 Apr; 446(7136):668-71. PubMed ID: 17410176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A robust platform for chemical genomics in bacterial systems.
    French S; Mangat C; Bharat A; Côté JP; Mori H; Brown ED
    Mol Biol Cell; 2016 Mar; 27(6):1015-25. PubMed ID: 26792836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-wall-inhibiting antibiotic combinations with activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli.
    Hickman RA; Hughes D; Cars T; Malmberg C; Cars O
    Clin Microbiol Infect; 2014 Apr; 20(4):O267-73. PubMed ID: 24118201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When more is less: Emergent suppressive interactions in three-drug combinations.
    Beppler C; Tekin E; White C; Mao Z; Miller JH; Damoiseaux R; Savage VM; Yeh PJ
    BMC Microbiol; 2017 May; 17(1):107. PubMed ID: 28477626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Studies on pathogenic Escherichia coli. (III) Multiple drug resistance of capsular polysaccharide-synthesizing Escherichia coli of clinical origins (author's transl)].
    Tseng CC; Chen MY; Lee LW
    Taiwan Yi Xue Hui Za Zhi; 1979 Jan; 78(1):7-16. PubMed ID: 376779
    [No Abstract]   [Full Text] [Related]  

  • 9. Engineered riboswitch as a gene-regulatory platform for reducing antibiotic resistance.
    Liu L; Wang S
    Methods Mol Biol; 2014; 1111():251-8. PubMed ID: 24549625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Active efflux of antibiotics as multiple-antibiotic-resistance mechanism in clinical strains of escherichia coli].
    Zhang X; Li J
    Zhonghua Yi Xue Za Zhi; 2000 Aug; 80(8):614-7. PubMed ID: 11798829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Studies on pathogenic Escherichia coli. (IV) Relation of capsular polysaccharide synthesis to antibiotic susceptibility, biochemical properties and pathogenicity (author's transl)].
    Tseng CC
    Taiwan Yi Xue Hui Za Zhi; 1980 May; 79(5):500-10. PubMed ID: 7003056
    [No Abstract]   [Full Text] [Related]  

  • 12. Metabolomics-Driven Exploration of the Chemical Drug Space to Predict Combination Antimicrobial Therapies.
    Campos AI; Zampieri M
    Mol Cell; 2019 Jun; 74(6):1291-1303.e6. PubMed ID: 31047795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The contribution of common rpsL mutations in Escherichia coli to sensitivity to ribosome targeting antibiotics.
    Pelchovich G; Schreiber R; Zhuravlev A; Gophna U
    Int J Med Microbiol; 2013 Dec; 303(8):558-62. PubMed ID: 23972615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the RNA chaperone Hfq on multidrug resistance in Escherichia coli.
    Yamada J; Yamasaki S; Hirakawa H; Hayashi-Nishino M; Yamaguchi A; Nishino K
    J Antimicrob Chemother; 2010 May; 65(5):853-8. PubMed ID: 20211861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of antibiotic resistance by gene expression profiles.
    Suzuki S; Horinouchi T; Furusawa C
    Nat Commun; 2014 Dec; 5():5792. PubMed ID: 25517437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRP regulator modulates multidrug resistance of Escherichia coli by repressing the mdtEF multidrug efflux genes.
    Nishino K; Senda Y; Yamaguchi A
    J Antibiot (Tokyo); 2008 Mar; 61(3):120-7. PubMed ID: 18503189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in the waaR gene of Escherichia coli which disrupt lipopolysaccharide outer core biosynthesis affect cell surface retention of group 2 capsular polysaccharides.
    Taylor CM; Goldrick M; Lord L; Roberts IS
    J Bacteriol; 2006 Feb; 188(3):1165-8. PubMed ID: 16428421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Array-based synthetic genetic screens to map bacterial pathways and functional networks in Escherichia coli.
    Babu M; Gagarinova A; Emili A
    Methods Mol Biol; 2011; 781():99-126. PubMed ID: 21877280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Array-based synthetic genetic screens to map bacterial pathways and functional networks in Escherichia coli.
    Babu M; Gagarinova A; Greenblatt J; Emili A
    Methods Mol Biol; 2011; 765():125-53. PubMed ID: 21815091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucosamine effects on growth and macromolecular synthesis in Escherichia coli.
    Bosmann HB
    Microbios; 1971 Jul; 4(13):57-64. PubMed ID: 4950293
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.